Company Overview
About ChromaCode
ChromaCode is a molecular diagnostics company developing High-Definition PCR (HDPCR), a breakthrough multiplexing platform that dramatically expands the number of analytes detectable in a single PCR well using standard laboratory instruments. By combining proprietary chemistry with amplitude modulation, multi-spectral encoding, and cloud-based decoding software, HDPCR enables labs to run panels for infectious disease, oncology biomarkers, transplant monitoring, and prenatal testing without expensive new hardware.
Business Model & Competitive Advantage
The company''s ChromaCode Cloud software automates signal decoding and delivers comprehensive results in minutes. ChromaCode has received FDA Emergency Use Authorization for COVID-19 testing and has commercially launched assays for tick-borne pathogens. Strategic investment from oncology-focused partners has advanced HDPCR applications into non-small-cell lung cancer and other solid tumor indications.
Competitive Landscape 2025–2026
ChromaCode is partnering with MedGenome to expand HDPCR-based diagnostics into India and the Middle East, broadening access to affordable, high-throughput molecular testing in underserved markets.
Key Differentiators
Strong Challenger
ChromaCode is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare ChromaCode with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ChromaCode? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ChromaCode Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ChromaCode vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →